Use of VIT E TPGS in preclinical formulation for oral bioavailability improvement of a NCE: a case study
BCS class IV drugs exhibit many characteristics that are problematic for effective oral delivery which most likely leads to low and variable bioavailability. Appropriate formulation design is, therefore, of key importance to establish a successful product from pre-clinical phase.
This study investigates the application of different technologies to improve the oral bioavailability of a BCS class IV New Chemical Entity (NCE) (Compound A) which exhibits very low solubility properties (<0.1 µg/ml over the physiological pH range) and low permeability. In order to overcome the inherent hurdles posed by this class of drugs, three alternative formulation approaches were screened:
- lipid-based formulation,
- solid dispersion via hot melt extrusion (HME)
Recently presented by our expert, Emanuela Del Vesco, in collaboration with Sunesis, at AAPS 2017, download your copy of our scientific poster today and discover more about VIT E TPGS in preclinical formulation.